循环 miR-409-3p 对 2 型糖尿病和冠心病患者主要不良心血管事件的预测价值

4区医学 Q3 Nursing

Endocrinologia, Diabetes y Nutricion Pub Date : 2024-07-30 DOI:10.1016/j.endinu.2024.05.009

Liang Cao , Xiangrong Pan , Ying Li , Wei Jia , Jiayang Huang , Jian Liu

{"title":"循环 miR-409-3p 对 2 型糖尿病和冠心病患者主要不良心血管事件的预测价值","authors":"Liang Cao , Xiangrong Pan , Ying Li , Wei Jia , Jiayang Huang , Jian Liu","doi":"10.1016/j.endinu.2024.05.009","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>To investigate the serum levels of miR-409-3p in patients with type 2 diabetes mellitus (T2DM) complicated with coronary heart disease (CHD) and its effect on high glucose (HG)-induced myocardial cell injury.</div></div><div><h3>Methods</h3><div>A total of 250 patients with T2DM admitted to our hospital from April 2020 through April 2022 were enrolled as the study subjects, and then grouped into T2DM+CHD (group #1) and T2DM (group #2). Real-time quantitative PCR (RT-qPCR) was used to measure the levels of serum miR-409-3p. The clinical performance of miR-409-3p was evaluated. The human cardiomyocyte AC16 cells were cultured in vitro and treated with HG. MTT assay and flow cytometry were performed to detect cell viability and apoptosis, respectively. Bioinformatic analyses were performed to explore the potential mechanism of miR-409-3p in T2DM complicated with CHD.</div></div><div><h3>Results</h3><div>The expression level of miR-409-3p was increased in the T2DM+CHD group and had a relative high diagnostic value for distinguishing patients with T2DM+CHD from patients with T2DM alone. Correlation analysis showed that serum miR-409-3p was positively associated with the Gensini score and adverse cardiovascular events; miR-409-3p knockdown alleviated HG-induced AC16 cell damage and reduced cell apoptosis. CREB1, BCL2, and SMAD2 were the top 3 hub genes of miR-409-3p.</div></div><div><h3>Conclusion</h3><div>Serum miR-409-3p may serve as a potential diagnostic and prognostic biomarker for predicting T2DM complicated with CHD and forecast adverse events. Targeting miR-409-3p may be a novel therapeutic strategy to intervene in the development of T2DM+CHD.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 9","pages":"Pages 372-379"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Predictive value of circulating miR-409-3p for major adverse cardiovascular events in patients with type 2 diabetes mellitus and coronary heart disease\",\"authors\":\"Liang Cao , Xiangrong Pan , Ying Li , Wei Jia , Jiayang Huang , Jian Liu\",\"doi\":\"10.1016/j.endinu.2024.05.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><div>To investigate the serum levels of miR-409-3p in patients with type 2 diabetes mellitus (T2DM) complicated with coronary heart disease (CHD) and its effect on high glucose (HG)-induced myocardial cell injury.</div></div><div><h3>Methods</h3><div>A total of 250 patients with T2DM admitted to our hospital from April 2020 through April 2022 were enrolled as the study subjects, and then grouped into T2DM+CHD (group #1) and T2DM (group #2). Real-time quantitative PCR (RT-qPCR) was used to measure the levels of serum miR-409-3p. The clinical performance of miR-409-3p was evaluated. The human cardiomyocyte AC16 cells were cultured in vitro and treated with HG. MTT assay and flow cytometry were performed to detect cell viability and apoptosis, respectively. Bioinformatic analyses were performed to explore the potential mechanism of miR-409-3p in T2DM complicated with CHD.</div></div><div><h3>Results</h3><div>The expression level of miR-409-3p was increased in the T2DM+CHD group and had a relative high diagnostic value for distinguishing patients with T2DM+CHD from patients with T2DM alone. Correlation analysis showed that serum miR-409-3p was positively associated with the Gensini score and adverse cardiovascular events; miR-409-3p knockdown alleviated HG-induced AC16 cell damage and reduced cell apoptosis. CREB1, BCL2, and SMAD2 were the top 3 hub genes of miR-409-3p.</div></div><div><h3>Conclusion</h3><div>Serum miR-409-3p may serve as a potential diagnostic and prognostic biomarker for predicting T2DM complicated with CHD and forecast adverse events. Targeting miR-409-3p may be a novel therapeutic strategy to intervene in the development of T2DM+CHD.</div></div>\",\"PeriodicalId\":37725,\"journal\":{\"name\":\"Endocrinologia, Diabetes y Nutricion\",\"volume\":\"71 9\",\"pages\":\"Pages 372-379\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrinologia, Diabetes y Nutricion\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2530016424001228\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Nursing\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinologia, Diabetes y Nutricion","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2530016424001228","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Nursing","Score":null,"Total":0}

引用次数: 0

摘要

方法选取我院 2020 年 4 月至 2022 年 4 月收治的 250 例 T2DM 患者作为研究对象，将其分为 T2DM + CHD（1 号组）和 T2DM（2 号组）。采用实时定量 PCR（RT-qPCR）技术测定血清 miR-409-3p 的水平。评估了 miR-409-3p 的临床表现。体外培养人心肌细胞 AC16 并用 HG 处理。分别用 MTT 法和流式细胞术检测细胞活力和凋亡。结果在 T2DM + CHD 组中，miR-409-3p 的表达水平升高，在区分 T2DM + CHD 患者与单纯 T2DM 患者方面具有相对较高的诊断价值。相关分析表明，血清 miR-409-3p 与 Gensini 评分和不良心血管事件呈正相关；敲除 miR-409-3p 可减轻 HG 诱导的 AC16 细胞损伤并减少细胞凋亡。结论血清 miR-409-3p 可作为一种潜在的诊断和预后生物标志物，用于预测 T2DM 并发心脏病和不良事件。以 miR-409-3p 为靶点可能是干预 T2DM + 冠心病发展的一种新型治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Predictive value of circulating miR-409-3p for major adverse cardiovascular events in patients with type 2 diabetes mellitus and coronary heart disease

Objectives

To investigate the serum levels of miR-409-3p in patients with type 2 diabetes mellitus (T2DM) complicated with coronary heart disease (CHD) and its effect on high glucose (HG)-induced myocardial cell injury.

Methods

A total of 250 patients with T2DM admitted to our hospital from April 2020 through April 2022 were enrolled as the study subjects, and then grouped into T2DM + CHD (group #1) and T2DM (group #2). Real-time quantitative PCR (RT-qPCR) was used to measure the levels of serum miR-409-3p. The clinical performance of miR-409-3p was evaluated. The human cardiomyocyte AC16 cells were cultured in vitro and treated with HG. MTT assay and flow cytometry were performed to detect cell viability and apoptosis, respectively. Bioinformatic analyses were performed to explore the potential mechanism of miR-409-3p in T2DM complicated with CHD.

Results

The expression level of miR-409-3p was increased in the T2DM + CHD group and had a relative high diagnostic value for distinguishing patients with T2DM + CHD from patients with T2DM alone. Correlation analysis showed that serum miR-409-3p was positively associated with the Gensini score and adverse cardiovascular events; miR-409-3p knockdown alleviated HG-induced AC16 cell damage and reduced cell apoptosis. CREB1, BCL2, and SMAD2 were the top 3 hub genes of miR-409-3p.

Conclusion

Serum miR-409-3p may serve as a potential diagnostic and prognostic biomarker for predicting T2DM complicated with CHD and forecast adverse events. Targeting miR-409-3p may be a novel therapeutic strategy to intervene in the development of T2DM + CHD.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Endocrinologia, Diabetes y Nutricion Nursing-Nutrition and Dietetics

CiteScore

2.10

自引率

0.00%

发文量

169

审稿时长

35 days

期刊介绍： Endocrinología, Diabetes y Nutrición is the official journal of the Spanish Society of Endocrinology and Nutrition (Sociedad Española de Endocrinología y Nutrición, SEEN) and the Spanish Society of Diabetes (Sociedad Española de Diabetes, SED), and was founded in 1954. The aim of the journal is to improve knowledge and be a useful tool in practice for clinical and laboratory specialists, trainee physicians, researchers, and nurses interested in endocrinology, diabetes, nutrition and related disciplines. It is an international journal published in Spanish (print and online) and English (online), covering different fields of endocrinology and metabolism, including diabetes, obesity, and nutrition disorders, as well as the most relevant research produced mainly in Spanish language territories. The quality of the contents is ensured by a prestigious national and international board, and by a selected panel of specialists involved in a rigorous peer review. The result is that only manuscripts containing high quality research and with utmost interest for clinicians and professionals related in the field are published. The Journal publishes Original clinical and research articles, Reviews, Special articles, Clinical Guidelines, Position Statements from both societies and Letters to the editor. Endocrinología, Diabetes y Nutrición can be found at Science Citation Index Expanded, Medline/PubMed and SCOPUS.